Quantcast
Last updated on April 18, 2014 at 12:39 EDT

Latest liver failure Stories

2014-04-16 09:48:04

Over 20 years after the fatal fialuridine trial, a study published this week in PLOS Medicine demonstrates that mice with humanized livers recapitulate the drug's toxicity. The work suggests that this mouse model should be added to the repertoire of tools used in preclinical screening of drugs for liver toxicity before they are given to human participants in clinical trials. A retrospective analysis by the US National Academy of Sciences of all preclinical fialuridine toxicity tests, which...

2014-03-04 16:20:56

Metabolic profiling of liver cells suggests new treatments for cirrhosis patients In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University-led team of researchers examined the metabolic breakdown that takes place in liver cells during late-stage cirrhosis and found clues that suggest new treatments to delay liver failure. More than 17,000 Americans are awaiting a liver transplant, and of those, about 1,500 will die this year while...

science laboratory
2014-02-24 05:23:59

Gladstone Institutes Joint Gladstone-UCSF study highlights novel reprogramming method; offers new hope for treating liver failure SAN FRANCISCO, CA—February 23, 2014 — The power of regenerative medicine now allows scientists to transform skin cells into cells that closely resemble heart cells, pancreas cells and even neurons. However, a method to generate cells that are fully mature—a crucial prerequisite for life-saving therapies—has proven far more difficult. But now,...

2013-12-02 23:02:17

OxyElite Pro Recall of Dietary Supplements Expanded to Include Raspberry Lemonade OxyElite Pro SuperThermo Powder, Following Reports of Liver Failure, Severe Liver Injury, and Non-Viral Hepatitis, Including Some Requiring Liver Transplant and One Death, Which the FDA Linked to Use of the “Fat-Burner” Products Columbus, OH (PRWEB) December 02, 2013 Wright & Schulte LLC, which is currently investigating potential OxyElite Pro lawsuits on behalf of individuals who suffered liver...

2013-11-19 23:02:28

Wright & Schulte LLC is Investigating Potential OxyElite Pro Recall Lawsuits After An OxyElite Pro Recall Was Issued Earlier This Month Following Reports of Liver Failure, Severe Liver Injury, and Non-Viral Hepatitis, Including Some Requiring Liver Transplant and One Death, Linked to Use of the “Fat-Burner” Products. Columbus, OH (PRWEB) November 19, 2013 Wright & Schulte LLC has stepped up its investigation of potential OxyElite Pro recall lawsuits, following the publication...

2013-11-18 08:28:41

Company receives first positive opinion in the European Union for Primary Sclerosing Cholangitis SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced that it has received positive opinions for four Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for LUM001. The company's lead drug candidate, LUM001, received the first positive...

2013-11-12 23:02:01

According to the FDA, an OxyElite Pro Recall Has Been Issued for All Lots and Sizes of OxyElite Pro Dietary Supplements, Following Reports of Liver Failure, Severe Liver Injury, and Non-Viral Hepatitis, Including Some Requiring Liver Transplant and One Death, Linked to Use of the “Fat-Burner” Products. Chicago, IL (PRWEB) November 12, 2013 Wright & Schulte LLC, an experienced harmful drug law firm representing individuals injured by defective drugs and dietary supplements, is now...

2013-10-29 08:32:43

Novel therapeutic approach to be evaluated for its ability to reduce elevated bile acid levels and associated severe itching SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the dosing of the first patient in the CLARITY Phase II study of its drug candidate LUM001 in patients with primary biliary cirrhosis (PBC). LUM001 is being developed as a possible therapy for a number of cholestatic...

2013-09-26 08:27:25

Company Pursuing Orphan Path to Development in Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced that it has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development for LUM001, the company's lead...

2012-10-13 04:03:22

Stem cell transfusions may someday replace the need for transplants in patients who suffer from liver failure caused by hepatitis B, according to a new study coming out of Beijing. . The results are published in the October issue of STEM CELLS Translational Medicine. Worldwide more than 500,000 people die each year from this condition. Durham, NC (PRWEB) October 11, 2012 Stem cell transfusions may someday replace the need for transplants in patients who suffer from liver failure caused by...